- S&P 500 7,659.44 −1.09%
- Dow Jones 52,002.41 −0.34%
- Nasdaq 26,713.03 +0.08%
- VIX 19.99 +21.45%
- 10-year Treasury 5.09% −0.01
- Dollar index 121.40 −0.14%
- WTI crude $101.91 +1.04%
Biotech calendar: November 2026
Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in November 2026, from ClinicalTrials.gov.
Trial readouts
187 trials: 72 phase 3 (including phase 2/3) and 115 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.
| Primary completion | Sponsor | Drug | Condition | Phase | Status | Record |
|---|---|---|---|---|---|---|
| Nov 2026 | AbbVie | Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg DoseA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | Atopic Dermatitis | Phase 3 | Active not recruiting | NCT06389136 |
| Nov 2026 | Akeso | cadonilimab, pulocimab, paclitaxelA Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric and Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | NCT06341335 |
| Nov 2026 | CG Oncology, Inc. | Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltosideA Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Non Muscle Invasive Bladder Cancer, Urologic Cancer and 2 more | Phase 3 | Active not recruiting | NCT06111235 |
| Nov 2026 | Camurus | CAM2029, Octreotide LAR, Lanreotide ATGA Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | Gastro-enteropancreatic Neuroendocrine Tumor | Phase 3 | Active not recruiting | NCT05050942 |
| Nov 2026 | Colgate-Palmolive Company | Colgate SNaP Total 10/10, 1.5 Taurate, Colgate Great Regular Flavor Toothpaste, Flat Trimmed Extra Clean TBTo Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis. | Plaque, Dental, Gingivitis | Phase 3 | Active not recruiting | NCT07605338 |
| Nov 2026 | DBV Technologies | DBV712 250 mcgSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | Allergy, Peanut Allergy | Phase 3 | Active not recruiting | NCT07003919 |
| Nov 2026 | Eli Lilly and Company | TirzepatideA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes, Obesity and 1 more | Phase 3 | Active not recruiting | NCT06962280 |
| Nov 2026 | Eli Lilly and Company | TirzepatideA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes, Obesity and 1 more | Phase 3 | Active not recruiting | NCT06914895 |
| Nov 2026 | Eli Lilly and Company | Retatrutide, TirzepatideA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Obesity | Phase 3 | Active not recruiting | NCT06662383 |
| Nov 2026 | Immunic AG | IMU-838 tabletsStudy to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Active not recruiting | NCT05201638 |
| Nov 2026 | Immunic AG | IMU-838 tabletsStudy to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | Phase 3 | Active not recruiting | NCT05134441 |
| Nov 2026 | Lynk Pharmaceuticals Co., Ltd | LNK01001A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis | Ankylosing Spondylitis | Phase 3 | Recruiting | NCT07237568 |
| Nov 2026 | Medicure Inc | Pyridoxal PhosphateOral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency | Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | Phase 3 | Recruiting | NCT04706013 |
| Nov 2026 | Nanjing Chia-tai Tianqing Pharmaceutical | NTQ5082 capsules 200 mg, Eculizumab InjectionA Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients | Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Not yet recruiting | NCT07177859 |
| Nov 2026 | NewAmsterdam Pharma Co N.V. | ObicetrapibCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | Atherosclerotic Cardiovascular Disease | Phase 3 | Active not recruiting | NCT05202509 |
| Nov 2026 | Nuance Hearing | Spectacle Hearing AidA Prospective, Open-label, Pivotal Study to Assess Spectacle Hearing Aid Safety and Efficacy | Hearing Loss Mixed | Phase 2/3 | Recruiting | NCT07282028 |
| Nov 2026 | Sandoz | CYB704, Ocrevus-EU, Ocrevus-USComparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing… | Relapsing Multiple Sclerosis | Phase 3 | Active not recruiting | NCT06847724 |
| Nov 2026 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1, capecitabine, gemcitabine and 1 moreA Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-N… | Nasopharyngeal Carcinoma | Phase 3 | Active not recruiting | NCT06118333 |
| Nov 2026 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | SKB264, PembrolizumabA Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung… | Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | NCT06448312 |
| Nov 2026 | Sinovac Biotech | experimental vaccine, active comparator vaccinePhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years | Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Active not recruiting | NCT07505888 |
| Nov 2026 | Waterstone Pharmaceutical (Wuhan) Co., LTD. | WS016A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia | Hyperkalemia | Phase 3 | Recruiting | NCT07251309 |
| Nov 2026 | Wooshin Labottach Co., Ltd. | Cosmetic patch containing urea applicated daily for 3 monthsStudy to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis | Nail Psoriasis, Nail Damage and 1 more | Phase 3 | Recruiting | NCT07029516 |
| Nov 2026 | medac GmbH | MethotrexateEfficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. | Moderate to Severe Atopic Dermatitis | Phase 3 | Recruiting | NCT06239311 |
| Nov 1, 2026 | Bristol-Myers Squibb | KarXTA Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | Bipolar-I Disorder With Mania or Mania With Mixed Features | Phase 3 | Recruiting | NCT06951698 |
| Nov 1, 2026 | Epygenix | Clemizole HClAn Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome | Lennox Gastaut Syndrome | Phase 3 | Recruiting | NCT05066217 |
| Nov 1, 2026 | Scholar Rock, Inc. | ApitegromabLong-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab | Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 and 8 more | Phase 3 | Active not recruiting | NCT05626855 |
| Nov 2, 2026 | AstraZeneca | AnifrolumabA Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Cutaneous Lupus Erythematosus | Phase 3 | Active not recruiting | NCT06015737 |
| Nov 2, 2026 | Bristol-Myers Squibb | KarXTA Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) | Bipolar Disorder Type I With Mania or Mania With Mixed Features | Phase 3 | Recruiting | NCT06951711 |
| Nov 2, 2026 | Teva Pharmaceutical Industries Ltd. | Fp/ABS, FP, ABSA Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Parti… | Asthma | Phase 3 | Active not recruiting | NCT06664619 |
| Nov 3, 2026 | Novartis | LOU064 (blinded)24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and … | Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | NCT05677451 |
| Nov 4, 2026 | CMG Pharmaceutical Co. Ltd | CMG190303(Dapagliflozin/Rosuvastatin)Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia | Dyslipidemia, Type 2 Diabetes | Phase 3 | Recruiting | NCT06772168 |
| Nov 9, 2026 | LEAF4Life, Inc. | LEAF-4L6715, Supportive CareEfficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome | Acute Respiratory Distress Syndrome | Phase 3 | Not yet recruiting | NCT06640777 |
| Nov 10, 2026 | Gan & Lee Pharmaceuticals Co., Ltd. | GZR4, Insulin Icodec groupA Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin | Diabetes | Phase 3 | Recruiting | NCT07165223 |
| Nov 10, 2026 | LaNova Medicines Zhejiang Co., Ltd. | LM-302, Apatinib, IrinotecanLM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | Phase 3 | Active not recruiting | NCT06351020 |
| Nov 11, 2026 | AstraZeneca | Trastuzumab deruxtecan, Taxane, Pertuzumab and 1 moreTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cance… | Breast Cancer; HER2-positive; Metastatic | Phase 3 | Active not recruiting | NCT04784715 |
| Nov 11, 2026 | Tasly Pharmaceutical Group Co., Ltd | Changkang granulesEfficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spl… | Diarrhea-predominant Irritable Boewl Syndrome | Phase 3 | Not yet recruiting | NCT06753890 |
| Nov 12, 2026 | Qilu Pharmaceutical Co., Ltd. | RelugolixEfficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | Heavy Menstrual Bleeding, Uterine Fibroids | Phase 3 | Recruiting | NCT06671548 |
| Nov 13, 2026 | Roche Holding | Inavolisib, Fulvestrant, Alpelisib and 3 moreA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-P… | Breast Cancer | Phase 3 | Recruiting | NCT05646862 |
| Nov 14, 2026 | BrightGene Bio-Medical Technology Co. | 5 mg BGM0504 Administered SC, 10 mg BGM0504 Administered SC, Semaglutide Administered SCA Study of BGM0504 in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Active not recruiting | NCT06716216 |
| Nov 14, 2026 | BrightGene Bio-Medical Technology Co. | 5 mg BGM0504 Administered SC, : 10 mg BGM0504 Administered SCA Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Active not recruiting | NCT06716203 |
| Nov 15, 2026 | Achieve Life Sciences, INC. | Cytisinicline, Behavioral SupportPhase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes | Vaping Cessation | Phase 3 | Not yet recruiting | NCT07392125 |
| Nov 16, 2026 | UCB | ZilucoplanA Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | Phase 2/3 | Recruiting | NCT06055959 |
| Nov 18, 2026 | Bristol-Myers Squibb | DeucravacitinibA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | Sjögren's Syndrome | Phase 3 | Active not recruiting | NCT05946941 |
| Nov 18, 2026 | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | ETOPOSIDE - Usual, ETOPOSIDE - StudyPharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms | Small Cell Lung Cancer | Phase 2/3 | Active not recruiting | NCT01064466 |
| Nov 18, 2026 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Abiraterone - Usual, Abiraterone - StudyPharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms | Prostate Cancer | Phase 2/3 | Active not recruiting | NCT03348670 |
| Nov 18, 2026 | Medicine Invention Design, Inc | ALECENSA - alectinib hydrochloride capsulePharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms | ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | Phase 2/3 | Active not recruiting | NCT05987956 |
| Nov 20, 2026 | Merck & Co. | Pembrolizumab, Carboplatin, Paclitaxel and 5 moreStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed… | Endometrial Neoplasms | Phase 3 | Active not recruiting | NCT04634877 |
| Nov 21, 2026 | Changchun GeneScience Pharmaceutical Co., Ltd. | Cabergoline tablets, Bromocriptine mesylate tabletsA Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets | Hyperprolactinemia | Phase 3 | Recruiting | NCT07124221 |
| Nov 23, 2026 | GSK | dTpaA Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healt… | Diphtheria-Tetanus-acellular Pertussis Vaccines | Phase 3 | Active not recruiting | NCT07596199 |
| Nov 23, 2026 | GSK | Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine and 4 moreA Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age | Chickenpox | Phase 3 | Recruiting | NCT06693895 |
| Nov 24, 2026 | Merck KGaA | AvelumabAvelumab Program Rollover Study | Solid Tumors | Phase 3 | Active not recruiting | NCT03815643 |
| Nov 24, 2026 | HTA Co., Ltd. | 177Lu-DOTATATE injection, Octreotide LAR (Long-acting release)A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With … | NETS Ga68 Lu177 | Phase 3 | Recruiting | NCT07057622 |
| Nov 24, 2026 | Bristol-Myers Squibb | KarXTA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Alzheimer Disease | Phase 3 | Recruiting | NCT06585787 |
| Nov 25, 2026 | Beijing InnoCare Pharma Tech Co., Ltd. | ICP-332 TabletsICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | Phase 3 | Recruiting | NCT06775860 |
| Nov 26, 2026 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | MT1013, CinacalcetStudy of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism | Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Recruiting | NCT07122401 |
| Nov 26, 2026 | GSK | Dostarlimab, Carboplatin, Paclitaxel and 1 moreA Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Pri… | Neoplasms | Phase 3 | Active not recruiting | NCT03981796 |
| Nov 28, 2026 | Haisco Pharmaceutical Group Co., Ltd. | HSK31858, tabletA Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis | Non-cystic Fibrosis Bronchiectasis | Phase 3 | Recruiting | NCT06660992 |
| Nov 28, 2026 | Sanofi | Yellow fever vaccine (live), Measles, combinations with mumps and rubella, live attenua…A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population | Yellow Fever Immunization | Phase 3 | Recruiting | NCT07103148 |
| Nov 29, 2026 | Pfizer | RimegepantA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | Menstrual Migraine | Phase 3 | Recruiting | NCT06641466 |
| Nov 30, 2026 | AUG Therapeutics | AVTX-803 (L-Fucose)A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II | Leukocyte Adhesion Deficiency | Phase 3 | Recruiting | NCT05462587 |
| Nov 30, 2026 | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | Plasmodium immunotherapyPlasmodium Immunotherapy for Advanced Ovarian Cancer | Advanced Ovarian Cancer | Phase 2/3 | Not yet recruiting | NCT05924776 |
| Nov 30, 2026 | Cytopeutics Sdn. Bhd. | Neuroncell-EXUCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX) | Acute Ischemic Stroke | Phase 2/3 | Recruiting | NCT06129175 |
| Nov 30, 2026 | Gritgen Therapeutics Co., Ltd. | GS1191-0445 injectionTo Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A | Hemophilia A | Phase 3 | Recruiting | NCT06833983 |
| Nov 30, 2026 | Roche Holding | Atezolizumab, BevacizumabA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | Cancer | Phase 3 | Active not recruiting | NCT03148418 |
| Nov 30, 2026 | InventisBio Co., Ltd | D-0502, FulvestrantA Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | Breast Cancer | Phase 3 | Recruiting | NCT06954961 |
| Nov 30, 2026 | Pharming Technologies B.V. | LeniolisibPediatric Patients Aged 4 to 11 Years With APDS | APDS | Phase 3 | Active not recruiting | NCT05438407 |
| Nov 30, 2026 | Sanofi | rilzabrutinibRilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan | Immune Thrombocytopenia | Phase 3 | Active not recruiting | NCT07216079 |
| Nov 30, 2026 | Saol Therapeutics Inc | SL1002, Normal SalinePhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | Osteoarthritis Knee Pain | Phase 3 | Active not recruiting | NCT07226258 |
| Nov 30, 2026 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | A166, T-DM1A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Trea… | HER2-positive Breast Cancer | Phase 3 | Active not recruiting | NCT06968585 |
| Nov 30, 2026 | Taisho Pharmaceutical Co., Ltd. | TS-172 20~60 mg/dayA Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | Hyperphosphatemia Patients on Hemodialysis | Phase 3 | Active not recruiting | NCT07548840 |
| Nov 30, 2026 | Tolmar Inc. | TOL2506, Tamoxifen, Letrozole Tablets and 2 moreOvarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | Breast Cancer | Phase 3 | Active not recruiting | NCT04906395 |
| Nov 30, 2026 | Zhejiang Wenda Pharma Technology LTD. | WD-890A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Trea… | Moderate to Severe Plaque Psoriasis | Phase 3 | Recruiting | NCT07672561 |
| Nov 2026 | AbbVie | Venetoclax, ObinutuzumabStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants Wi… | Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Recruiting | NCT04895436 |
| Nov 2026 | AbbVie | Budigalimab, Livmoniplimab, Lenvatinib and 1 moreStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV … | Hepatocellular Carcinoma | Phase 2 | Active not recruiting | NCT05822752 |
| Nov 2026 | AbbVie | Mirvetuximab soravtansine, CarboplatinMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epi… | High Grade Ovarian Cancer, Primary Peritoneal Cancer and 1 more | Phase 2 | Active not recruiting | NCT05456685 |
| Nov 2026 | AbbVie | ABBV-932, Antidepressant Therapy (ADT)Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants … | Generalized Anxiety Disorder (GAD) | Phase 2 | Recruiting | NCT06846320 |
| Nov 2026 | Admetsys Corporation | glucose and insulin infusionsInsulin Balanced Infusion System | Hyperglycemia, Diabetes | Phase 1/2 | Active not recruiting | NCT01291719 |
| Nov 2026 | Alkermes | ALKS 2680A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | Idiopathic Hypersomnia | Phase 2 | Active not recruiting | NCT06843590 |
| Nov 2026 | Anbogen Therapeutics, Inc. | ABT-101Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients | Advanced Solid Tumor, Non Small Cell Lung Cancer and 1 more | Phase 1/2 | Recruiting | NCT05532696 |
| Nov 2026 | Apogee Therapeutics, Inc. | APG777A Study Evaluating APG777 in Atopic Dermatitis | Atopic Dermatitis | Phase 2 | Active not recruiting | NCT06395948 |
| Nov 2026 | Aptose Biosciences Inc. | Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous InfusionClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed… | Leukemia, Myeloid, Acute, Refractory AML and 3 more | Phase 1/2 | Recruiting | NCT03850574 |
| Nov 2026 | Arthrosi Therapeutics | AR882 75 mg, XOI Low Dose, XOI High DoseEvaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients | Gout, Gouty Arthritis and 5 more | Phase 2 | Active not recruiting | NCT07116746 |
| Nov 2026 | Atossa Therapeutics, Inc. | (Z)-endoxifen, goserelin(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | Breast Neoplasms, Invasive Breast Cancer and 2 more | Phase 2 | Active not recruiting | NCT05607004 |
| Nov 2026 | Avistone Biotechnology Co., Ltd. | PLB1004Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EG… | Non-Small-Cell Lung Cancer | Phase 2 | Recruiting | NCT07336732 |
| Nov 2026 | BRIM Biotechnology Inc. | BRM421 Ophthalmic Solution, 0.03%, Artificial Tear, BRM421 Ophthalmic Solution, 0.06%A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease | Dry Eye Disease (DED), Keratoconjunctivitis Sicca | Phase 2 | Not yet recruiting | NCT07078955 |
| Nov 2026 | BeOne Medicines Ltd. | Sonrotoclax, ZanubrutinibA Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Ly… | Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | NCT06637501 |
| Nov 2026 | BeOne Medicines Ltd. | Sonrotoclax, Dexamethasone, Carfilzomib and 2 moreA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone … | Relapsed/Refractory Multiple Myeloma | Phase 1/2 | Recruiting | NCT04973605 |
| Nov 2026 | Beckley Psytech Limited | BPL-003An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression | Treatment Resistant Depression | Phase 2 | Recruiting | NCT05660642 |
| Nov 2026 | BeOne Medicines Ltd. | Tislelizumab (BGB-A317)Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors | MSI-H/dMMR Solid Tumors | Phase 2 | Recruiting | NCT03736889 |
| Nov 2026 | Bexion Pharmaceuticals, Inc. | BXQ-350BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma | Metastatic Colorectal Carcinoma, Neuropathy | Phase 1/2 | Active not recruiting | NCT05322590 |
| Nov 2026 | BioNTech | RO7198457 intravenous (IV), Observational group (no intervention)A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (Hi… | Colorectal Cancer Stage II, Colorectal Cancer Stage III | Phase 2 | Active not recruiting | NCT04486378 |
| Nov 2026 | Bright Minds Biosciences INC. | BMB-101A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome. | Prader-Willi Syndrome | Phase 2 | Not yet recruiting | NCT07266324 |
| Nov 2026 | Calluna Pharma AS | CAL101A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | NCT06736990 |
| Nov 2026 | Cardiff Oncology, Inc. | Onvansertib, FOLFIRI, Bevacizumab and 1 moreStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Beva… | Metastatic Colorectal Cancer, CRC and 1 more | Phase 2 | Active not recruiting | NCT06106308 |
| Nov 2026 | Sino Biopharmaceutical Limited | TQB2868 injection, Gemcitabine injection, Albumin paclitaxel injection and 1 moreClinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Ne… | Pancreatic Neoplasms | Phase 2 | Recruiting | NCT06767813 |
| Nov 2026 | Eli Lilly and Company | LY4515100A Study of LY4515100 in Participants With Pain Following Third Molar Removal | Acute Pain, Molar and 2 more | Phase 2 | Recruiting | NCT07511816 |
| Nov 2026 | Eli Lilly and Company | LY3938577, DegludecA Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | Diabetes Mellitus, Type 2 | Phase 2 | Active not recruiting | NCT07215312 |
| Nov 2026 | Ferrer Internacional S.A. | FNP-223A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy | Phase 2 | Active not recruiting | NCT06355531 |
| Nov 2026 | Forge Biologics, Inc | FBX-101Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT | Krabbe Disease | Phase 1/2 | Active not recruiting | NCT05739643 |
| Nov 2026 | Haisco Pharmaceutical Group Co., Ltd. | HSK55718 dose level 1, HSK55718 dose level 2, HSK55718 dose level 3 and 1 moreA Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Orthopedic Surgery | Pain After Surgery | Phase 2 | Not yet recruiting | NCT07551739 |
| Nov 2026 | IGC Pharma, Inc. | IGC-AD1-ActiveClinical Trial on Agitation in Alzheimer's Dementia | Alzheimer Disease, Agitation,Psychomotor and 3 more | Phase 2 | Active not recruiting | NCT05543681 |
| Nov 2026 | ImmunityBio, Inc. | N-803 and BCG, N-803 and GemcitabineClinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Not yet recruiting | NCT06829823 |
| Nov 2026 | Jiangsu Hengrui Medicine | Bupivacaine Liposome Injection, Bupivacaine Hydrochloride InjectionA Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery | Local Analgesia Via Nerve Block | Phase 2 | Recruiting | NCT06529432 |
| Nov 2026 | Jiangsu Hengrui Medicine | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapiesA Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. | HER2-expressing Advanced Solid Tumors | Phase 1/2 | Recruiting | NCT06015048 |
| Nov 2026 | KeyBioscience AG | KBP-336Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis | Osteoarthritis in the Knee, Obesity | Phase 2 | Recruiting | NCT06833749 |
| Nov 2026 | Kiora Pharmaceuticals Inc | KIO-104Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema | Macular Edema | Phase 2 | Recruiting | NCT06825702 |
| Nov 2026 | MediLink Therapeutics (Suzhou) Co., Ltd. | YL202 should be intravenously infusedA Study of YL202 in Selected Patients With Advanced Solid Tumors | NSCLC, Breast Cancer and 2 more | Phase 2 | Recruiting | NCT06107686 |
| Nov 2026 | NeuShen Therapeutics | NS-136A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia | Schizophrenia(Acute) | Phase 2 | Enrolling by invitation | NCT07521683 |
| Nov 2026 | NewAmsterdam Pharma Co N.V. | obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeksImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | Dyslipidemias | Phase 2 | Recruiting | NCT06496243 |
| Nov 2026 | Pacira Pharmaceuticals, Inc. | Enekinragene Inzadenovec (PCRX-201)A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee | Osteoarthritis (OA) of the Knee | Phase 2 | Recruiting | NCT06884865 |
| Nov 2026 | Pharmazz, Inc. | Normal Saline along with standard treatment, Sovateltide along with standard treatmentAssess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy | Hypoxic-Ischemic Encephalopathy, Neonatal Asphyxia and 1 more | Phase 2 | Recruiting | NCT05514340 |
| Nov 2026 | ReCode Therapeutics | RCT2100, IvacaftorA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | Cystic Fibrosis | Phase 2 | Active not recruiting | NCT06237335 |
| Nov 2026 | Reunion Neuroscience | RE104 for InjectionRE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Adjustment Disorder | Phase 2 | Recruiting | NCT07002034 |
| Nov 2026 | SciNeuro | SNP318A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients | Diabetic Macular Edema, DME | Phase 2 | Not yet recruiting | NCT07199777 |
| Nov 2026 | Jiangsu Hengrui Medicine | HRS-1780 TabletsA Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism | Primary Aldosteronism | Phase 2 | Active not recruiting | NCT07470983 |
| Nov 2026 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | TQH2722 injectionClinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis | Phase 2 | Recruiting | NCT07398859 |
| Nov 2026 | Sichuan Baili Pharmaceutical Co., Ltd. | SI-B001, SI-B003A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head a… | Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | NCT06668961 |
| Nov 2026 | Stemline Therapeutics, Inc. | ElacestrantELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study | Metastatic Breast Cancer | Phase 2 | Active not recruiting | NCT05596409 |
| Nov 2026 | Jiangsu Hengrui Medicine | SHR-1681A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors | Malignant Solid Tumors | Phase 1/2 | Recruiting | NCT06737731 |
| Nov 2026 | TBF Genie Tissulaire | SclerFIX-IPUse of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis | Osteoarthritis Hand | Phase 2 | Active not recruiting | NCT06038331 |
| Nov 2026 | TYK Medicines, Inc | TYK-00540, EnzalutamideStudy of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） | mCRPC | Phase 1/2 | Not yet recruiting | NCT07104643 |
| Nov 2026 | Traws Pharma, Inc. | TRX-100, Influenza A/France/759/2021 (H1N1) virusPhase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model | Influenza | Phase 2 | Not yet recruiting | NCT07503405 |
| Nov 2026 | Tyra Biosciences, Inc. | TYRA-300Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma and 12 more | Phase 1/2 | Active not recruiting | NCT05544552 |
| Nov 2026 | VIR Biotechnology | Tobevibart, Elebsiran, BulevirtideA Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | Viral Hepatitis | Phase 2 | Active not recruiting | NCT07142811 |
| Nov 2026 | Argenx SE | Empasiprubart IVA Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | Dermatomyositis, Myositis | Phase 2 | Active not recruiting | NCT06284954 |
| Nov 1, 2026 | Corbus Pharmaceuticals | CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibodyFirst-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Solid Tumor | Phase 1/2 | Recruiting | NCT06603844 |
| Nov 1, 2026 | ML Bio Solutions, Inc. | BBP-418Study of BBP-418 in Patients With LGMD2I | LGMD2I | Phase 2 | Active not recruiting | NCT04800874 |
| Nov 1, 2026 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | ZGGS18 for InjectionStudy of ZGGS18 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT05584800 |
| Nov 2, 2026 | GSK | DostarlimabA Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer | Neoplasms, Rectal | Phase 2 | Active not recruiting | NCT05723562 |
| Nov 2, 2026 | Keymed Biosciences Co.Ltd | CM512 injectionStudy of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) | Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | NCT07166211 |
| Nov 2, 2026 | Regeneron Pharmaceuticals | cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimabA Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4… | Melanoma | Phase 2 | Active not recruiting | NCT06190951 |
| Nov 5, 2026 | AstraZeneca | AZD9750, AZD5305A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Antica… | Prostate Cancer | Phase 1/2 | Active not recruiting | NCT07336446 |
| Nov 5, 2026 | Incyte | Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib and 1 moreRollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB0… | B-Cell Malignancies | Phase 2 | Active not recruiting | NCT04509700 |
| Nov 6, 2026 | Haisco Pharmaceutical Group Co., Ltd. | HSK44459 dose level 1, HSK44459 dose level 2A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis | Psoriasis | Phase 2 | Not yet recruiting | NCT07150988 |
| Nov 9, 2026 | GSK | Pembrolizumab, Dostarlimab, Belrestotug and 1 moreA Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Canc… | Lung Cancer, Non-Small Cell | Phase 2 | Active not recruiting | NCT05565378 |
| Nov 10, 2026 | HELP Therapeutics Co., Ltd. | HiCM-188 therapyEpicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure | Heart Failure | Phase 1/2 | Active not recruiting | NCT06340048 |
| Nov 11, 2026 | Precigen, Inc | PRGN-2009 plus PembrolizumabPRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | Cervical Cancer, HPV-Related Carcinoma and 3 more | Phase 2 | Recruiting | NCT06157151 |
| Nov 12, 2026 | Longbio Pharma (Suzhou) Co., Ltd. | LP-005 InjectionEfficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe Periodontitis | Periodontitis | Phase 2 | Not yet recruiting | NCT07603713 |
| Nov 13, 2026 | Regeneron Pharmaceuticals | OlatorepatideStudy of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US | Overweight or Obesity | Phase 2 | Active not recruiting | NCT07431086 |
| Nov 13, 2026 | Regeneron Pharmaceuticals | REGN7075, Cemiplimab, Platinum-based doublet chemotherapy and 2 moreA Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Advanced Solid Tumors | Phase 1/2 | Active not recruiting | NCT04626635 |
| Nov 13, 2026 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | SYHA1813, SG001, HB1801 and 6 moreSafety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid … | Unresectable Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Not yet recruiting | NCT06682611 |
| Nov 15, 2026 | PolyActiva Pty Ltd | PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic SolutionEvaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension | Glaucoma, Open-Angle, Ocular Hypertension | Phase 2 | Active not recruiting | NCT06964191 |
| Nov 17, 2026 | AstraZeneca | AZD0901, 5-Fluorouracil, Leucovorin and 4 moreAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Gastric Cancer, Gastroesophageal Junction Cancer and 2 more | Phase 2 | Recruiting | NCT06219941 |
| Nov 18, 2026 | Roche Holding | SatralizumabA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | Phase 2 | Active not recruiting | NCT06450639 |
| Nov 18, 2026 | ToLymph Inc. | SMS001An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | NCT06693336 |
| Nov 19, 2026 | Roche Holding | RO7269162A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disea… | Alzheimer's Disease | Phase 2 | Active not recruiting | NCT06402838 |
| Nov 19, 2026 | Johnson & Johnson | JNJ-95597528A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic | Phase 2 | Active not recruiting | NCT07230860 |
| Nov 20, 2026 | Incyte | povorcitinib, ICS-LABAA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | Moderate to Severe Asthma | Phase 2 | Active not recruiting | NCT05851443 |
| Nov 20, 2026 | Skye Bioscience, Inc. | Nimacimab injection, semaglutide injection, Nimacimab 300 mg injectionStudy to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo | Obesity | Phase 2 | Active not recruiting | NCT06577090 |
| Nov 22, 2026 | Haisco Pharmaceutical Group Co., Ltd. | HSK55718 dose level1, HSK55718 dose level2, HSK55718 dose level 3 and 1 moreA Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery | Pain After Surgery | Phase 2 | Recruiting | NCT07533786 |
| Nov 22, 2026 | Resverlogix Corp | apabetaloneA Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis | Kidney Failure, Chronic | Phase 1/2 | Not yet recruiting | NCT03160430 |
| Nov 22, 2026 | Shanghai Henlius Biotech | HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Thera… | Nasopharyngeal Carcinoma (NPC) | Phase 2 | Recruiting | NCT06839066 |
| Nov 23, 2026 | GSK | Dostarlimab, CAPEOXA Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatc… | Neoplasms, Colon | Phase 2 | Recruiting | NCT06567782 |
| Nov 24, 2026 | AstraZeneca | AZD0754, AZD2287Study of AZD0754 in Participants With Metastatic Prostate Cancer | Metastatic Prostate Cancer | Phase 1/2 | Recruiting | NCT06267729 |
| Nov 24, 2026 | CanSino Biologics | 24-valent pneumococcal polysaccharide conjugate vaccine (C…, PCV24 vaccine (dose H), PCV24 vaccine (dose M) and 6 moreClinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) | Streptococcus Pneumoniae Infection | Phase 1/2 | Recruiting | NCT07600983 |
| Nov 24, 2026 | Tectonic Therapeutic, Inc. | TX000045- Dose A, TX000045- Dose BA Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction | Phase 2 | Active not recruiting | NCT06616974 |
| Nov 28, 2026 | TrueBinding, Inc. | TB006A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | Parkinson's Disease (PD) | Phase 2 | Active not recruiting | NCT06773962 |
| Nov 30, 2026 | Akeso | AK104+lenvatinib, lenvatinibA Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | HCC, Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | NCT06984718 |
| Nov 30, 2026 | Amgen | Anvumetostat, Docetaxel, Comparator Anvumetostat Test TabletA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | Advanced MTAP-null Solid Tumors | Phase 1/2 | Active not recruiting | NCT05094336 |
| Nov 30, 2026 | Arvinas Inc. | ARV-806A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | KRAS G12D Mutation, Advanced Solid Cancer | Phase 1/2 | Active not recruiting | NCT07023731 |
| Nov 30, 2026 | AstraZeneca | Durvalumab, Tremelimumab, LenvatinibDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma | Phase 2 | Active not recruiting | NCT07081633 |
| Nov 30, 2026 | Aura Biosciences | AU-011, SCS Microinjector, LaserSuprachoroidal Administration in Subjects With Metastases to the Choroid | Eye Cancer, Primary Cancer | Phase 2 | Recruiting | NCT06643884 |
| Nov 30, 2026 | Bavarian Nordic | Jynneos, MVA-BN (Quail)Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells | Monkeypox (Mpox) | Phase 2 | Active not recruiting | NCT07199569 |
| Nov 30, 2026 | BeyondBio Inc. | BEY1107, CapecitabineA Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | Phase 1/2 | Recruiting | NCT05093907 |
| Nov 30, 2026 | BeyondBio Inc. | BEY1107, GemcitabineEvaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer | Locally Advanced or Metastatic Pancreatic Cancer | Phase 1/2 | Recruiting | NCT03579836 |
| Nov 30, 2026 | Bio-Thera Solutions | BAT8008 injection, BAT1308 injectionA Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT800… | Advanced Solid Tumors | Phase 1/2 | Active not recruiting | NCT06341114 |
| Nov 30, 2026 | BioAge Labs, Inc. | Oral BGE-102A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Fa… | Obesity and Cardiovascular Risk | Phase 2 | Active not recruiting | NCT07656727 |
| Nov 30, 2026 | CSPC Pharmaceutical Group | SYS6010, Osimertinib, Pemetrexed and 2 moreA Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resect… | Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | NCT07256509 |
| Nov 30, 2026 | Bristol-Myers Squibb | CC-92480, Bortezomib, Dexamethasone and 4 moreA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With St… | Multiple Myeloma | Phase 1/2 | Active not recruiting | NCT03989414 |
| Nov 30, 2026 | Roche Holding | Alectinib, Entrectinib, Vemurafenib and 7 moreA Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer | Phase 2 | Recruiting | NCT04302025 |
| Nov 30, 2026 | Immunocore | IMC-R117C, Chemotherapy drug, Kinase inhibitor and 2 morePhase 1/2 Study of IMC-R117C in Selected Advanced Cancers | Cancer, HLA-A*02:01-positive | Phase 1/2 | Recruiting | NCT06840119 |
| Nov 30, 2026 | Innovent Biologics | Pemetrexed, Cisplatin, IBI363 and 2 moreIBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous… | Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Recruiting | NCT07122687 |
| Nov 30, 2026 | Medicenna Therapeutics Corp. | MDNA11, Pembrolizumab (KEYTRUDA®)A Beta-only IL-2 ImmunoTherapY Study | Advanced Solid Tumor, Unresectable Solid Tumor and 35 more | Phase 1/2 | Recruiting | NCT05086692 |
| Nov 30, 2026 | Moderna | mRNA-3745A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) | Glycogen Storage Disease | Phase 1/2 | Active not recruiting | NCT05095727 |
| Nov 30, 2026 | Mundipharma Research Limited | Rezafungin AcetateRezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options | Chronic Pulmonary Aspergillosis | Phase 2 | Active not recruiting | NCT06794554 |
| Nov 30, 2026 | Viatris | MR-130A-01 contraceptive transdermal patch, containing nor…Investigating Ovulation Inhibition for Use as a Contraceptive | Contraception | Phase 2 | Recruiting | NCT07365904 |
| Nov 30, 2026 | Neonc Technologies Holdings, INC. | Perillyl alcoholSafety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | Glioblastoma Multiforme | Phase 1/2 | Active not recruiting | NCT02704858 |
| Nov 30, 2026 | NeuroPace Inc | RNS SystemRNS System LGS Feasibility Study | Epilepsy, Lennox Gastaut Syndrome and 3 more | Phase 2 | Active not recruiting | NCT05339126 |
| Nov 30, 2026 | Nuwacell Biotechnologies Co., Ltd. | NCR100, 0.9% Normal salineA Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA） | Knee Osteoarthritis | Phase 1/2 | Not yet recruiting | NCT06741098 |
| Nov 30, 2026 | OncoC4, Inc. | ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetanONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer | Phase 1/2 | Active not recruiting | NCT05682443 |
| Nov 30, 2026 | OriCell Therapeutics Co., Ltd. | OriCAR-017OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM | Relapsed and/or Refractory Multiple Myeloma | Phase 1/2 | Recruiting | NCT06182696 |
| Nov 30, 2026 | Ranok Therapeutics (Hangzhou) Co., Ltd. | RNK08954To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. | KRAS G12D Mutations, Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Recruiting | NCT07303465 |
| Nov 30, 2026 | Shanghai JMT-Bio Inc. | JMT108Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors | Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors | Phase 1/2 | Recruiting | NCT07280832 |
| Nov 30, 2026 | Solid Biosciences Inc. | SGT-001Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | Duchenne Muscular Dystrophy | Phase 1/2 | Active not recruiting | NCT03368742 |
| Nov 30, 2026 | Takeda Pharmaceutical Company | TAK-360A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | Narcolepsy Type 2 | Phase 2 | Recruiting | NCT06952699 |
| Nov 30, 2026 | Takeda Pharmaceutical Company | TAK-360A Study of TAK-360 in Adults With Idiopathic Hypersomnia | Idiopathic Hypersomnia | Phase 2 | Recruiting | NCT06812078 |
| Nov 30, 2026 | uniQure N.V. | AAV9-hSyn1-miGRIK2AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | Mesial Temporal Lobe Epilepsy | Phase 1/2 | Recruiting | NCT06063850 |
Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. Advisory committees: the FDA advisory committee calendar. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.